[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-nervous-system-cns-metastases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-nervous-system-cns-metastases":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642141","a-phase-ii-observational-clinical-study-on-the-relationship-between-cerebrospinal-fluid-drug-concentration-and-efficacy-of-trastuzumab-deruxtecan-in-central-nervous-system-metastatic-breast-cancer-100642141",false,"NCT07653893","A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer","A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration of Trastuzumab Deruxtecan and Efficacy in Central Nervous System Metastatic Breast Cancer","BCBM006","Inclusion Criteria:\n\n* 1\\. ≥18 years（2007-06）, any gender. 2. ECOG Performance Status 0-2. 3. Evidence of local recurrence or metastatic breast cancer not amenable to curative surgery or radiotherapy, and planned for intravenous trastuzumab deruxtecan treatment.\n\n  4\\. Expected survival time ≥8 weeks. 5. Provision of sufficient fresh tissue specimen or ≥10 unstained slides of tumor sample (primary and\u002For metastatic site) for biomarker analysis prior to treatment (intracranial metastatic lesion specimens preferred).\n\n  6\\. Cohort 2 (Experimental Cohort): Presence of brain parenchymal metastases confirmed by contrast-enhanced brain MRI, with at least one measurable brain lesion not previously irradiated, evaluable per RECIST 1.1 criteria.\n\n  7\\. Patients receiving mannitol, steroids, or anticonvulsant therapy prior to the first dose are eligible if the drug doses are stable for at least one week without requiring an increase, and neurological symptoms are stable for ≥1 week.\n\n  8\\. Organ function levels must meet the following requirements:\n  1. Hematology:\n\n     * ANC≥1.5×109\u002FL;\n     * PLT≥75×109\u002FL;\n     * Hb≥90 g\u002FL (allowing blood transfusion or medication to ensure hemoglobin content);\n  2. Coagulation function: APTT≤1.5×ULN；PT≤1.5×ULN;\n  3. Blood Chemistry:\n\n     • TBIL≤1.5×ULN;\n     * ALT and AST≤3×ULN (≤ 5.0×ULN for liver metastases);\n     * Creatinine ≤1.5 × ULN or Creatinine Clearance ≥50 mL\u002Fmin (Cockcroft-Gault formula);\n  4. Cardiac Ultrasound: LVEF ≥50%;\n  5. 12-Lead ECG: Fridericia-corrected QT interval (QTcF) \\\u003C470 ms for females, \\\u003C450 ms for males; 9. Voluntary participation in this study, signed informed consent, good compliance, and willingness to cooperate with follow-up.\n\nExclusion Criteria:\n\n* 1\\. Presence of uncontrolled third-space fluid accumulation (e.g., large pleural effusion or ascites) not manageable by drainage or other methods, deemed unsuitable for enrollment by the investigator.\n\n  2\\. Previous treatment with an anti-HER2 ADC drug carrying the same payload resulting in resistance. Patients who discontinued prior ADC therapy for other reasons, including but not limited to toxicity, are eligible.\n\n  3\\. Adverse reactions from prior anti-tumor therapy have not recovered to ≤ Grade 1 per CTCAE v5.0 (except for ≤ Grade 2 toxicities judged by the investigator as having no safety risk, such as alopecia or long-term toxicities from radiotherapy).\n\n  4\\. History of other malignancies within the past 5 years, excluding cured carcinoma in situ of the cervix, basocellular skin carcinomas, or cutaneous squamous cell carcinoma.\n\n  5\\. History of severe cardiovascular or cerebrovascular diseases, including but not limited to:\n  * Severe cardiac rhythm or conduction abnormalities requiring clinical intervention, such as ventricular arrhythmia, II-III degree atrioventricular block, etc.\n  * Cardiac insufficiency of Class III\\~IV according to the New York Heart Association (NYHA) criteria.\n  * Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other Grade 3 or higher cardiovascular\u002Fcerebrovascular events within 6 months prior to the first dose.\n  * Clinically uncontrolled hypertension.\n  * Any factors increasing the risk of QTc prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, use of any concomitant medications known or suspected to prolong the QT interval; Known history of allergy to any component of the study drug.\n\n    6\\. History of immunodeficiency disease, including other acquired or congenital immunodeficiency diseases, history of organ transplantation, allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation.\n\n    7\\. HIV infection, active HBV or HCV infection. The following exceptions are allowed:\n  * Patients positive for hepatitis B surface antigen (HBsAg), with or without positive hepatitis B core antibody (anti-HBc), if HBV DNA \\\u003C 1000 IU\u002FmL or below the lower limit of detection at the research center, and per investigator assessment excluding active infection based on clinical treatment and presentation.\n  * Hepatitis C (HCV) antibody-positive patients who are HCV RNA-negative. 8. History of autoimmune diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis, or glomerulonephritis, except for autoimmune thyroid dysfunction treated with stable-dose hormone replacement therapy.\n\n    9\\. Patients with known idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, interstitial lung disease, severe radiation pneumonitis, or evidence of active pneumonia on screening chest CT scan.\n\n    10\\. Inability to cooperate with lumbar puncture. 11. Vaccination with any vaccine within 28 days prior to the first dose. 12. Pregnant or lactating female patients; female patients of childbearing potential with baseline pregnancy test positive; or patients unwilling to use effective contraception throughout the trial period.\n\n    13\\. Presence of any concomitant disease, per investigator judgment, that seriously endangers the patient's safety or affects the patient's ability to complete the study (including but not limited to severe hypertension that cannot be controlled by medication, severe diabetes, active infection, thyroid disease, etc.).\n\n    14\\. Any other circumstances where the researcher deems the patient unsuitable for participation in this study.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","28 Days","OBSERVATIONAL","Approximately 5-15% breast cancer patients develop brain metastases. Current local treatments (surgery\u002Fradiotherapy) are associated with significant complications, and systemic treatments have limited efficacy. Although new-generation ADC drugs, such as trastuzumab deruxtecan, have demonstrated breakthrough efficacy in patients with brain metastases, the mechanisms of action are not fully elucidated, moreover the current treatment regimens still have limitations for patients with HER2-low expressing, safer and more effective systemic treatment options are urgently needed to improve patient survival. BCBM-006 is an open-label, prospective, single-arm, single-center Phase II clinical study to evaluate the relationship between cerebrospinal fluid drug concentration and efficacy of trastuzumab deruxtecan in central nervous system metastatic breast cancer, and explore the incidence of leptomeningeal metastases diagnosed via lumbar puncture in patients with brain parenchymal metastases, facilitate early intervention to improve prognosis.",[26,27],"Central Nervous System (CNS) Metastases","Breast Cancer","RECRUITING","2026-06-13",{"date":31,"type":32},"2026-06-17","ACTUAL",{"date":34,"type":32},"2025-06-11",{"date":36,"type":21},"2028-06",{"name":38,"class":39},"Fudan University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100639103","phase-1-material-balance-of-14czorifertinib-in-healthy-adult-male-participants-in-china-100639103","NCT07620951","Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China","Phase I Clinical Study on Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China","Inclusion Criteria:\n\n1. Healthy Chinese males;\n2. Age at the time of signing the informed consent form: 18-45 years (inclusive);\n3. Body mass index (BMI) ranging from 19-26 kg\u002Fm2 (inclusive), with a body weight of no less than 50 kg;\n4. Fully understand the purpose and requirements of this study and voluntarily sign the informed consent form;\n5. Be able to communicate well with the investigators and complete the trial according to the protocol.\n6. The 14C content in plasma and urine samples obtained during screening are within general environmental 14C background levels. Directly analyzed plasma samples must have values ≤150 pMC, and urine samples containing petroleum-based carbon carriers must have values ≤50 pMC.\n\nExclusion Criteria:\n\nAncillary Examinations:\n\n1. Abnormal findings from comprehensive physical examination, vital signs, laboratory tests (hematology, blood biochemistry, coagulation function, urinalysis, routine stool + occult blood, thyroid function), 12-lead ECG, chest X-ray (posteroanterior view), abdominal ultrasound, digital rectal examination, etc., that are judged by the investigator as clinically significant.\n2. Resting corrected QT interval (Fridericia correction, QTcF = QT\u002FRR1\u002F3) obtained from 12-lead ECG \\>450 ms in males, or other abnormalities judged by the investigator as clinically significant.\n3. Positive result for any of the following: hepatitis B surface antigen or hepatitis B e antigen, hepatitis C virus antibody, Treponema pallidum antibody, or human immunodeficiency virus antigen\u002Fantibody combination test (HIV-Ag\u002FAb).\n4. Abnormal findings from ophthalmic examination (slit lamp, intraocular pressure, fundus photography) that are clinically significant.\n\n   Medication History:\n5. Use of any drugs that inhibit or induce the drug-metabolizing enzyme CYP3A4 within 30 days prior to the screening period.\n6. Use of any prescription drugs, over-the-counter drugs, herbal medicines, or food supplements (e.g., vitamins, calcium supplements) within 14 days prior to the screening period.\n\n   Medical and Surgical History:\n7. History of any clinically serious disease or condition that the investigator believes may affect the trial results, including but not limited to circulatory, respiratory, endocrine, nervous, digestive, urinary, hematologic, immune, psychiatric, or metabolic diseases;\n8. History of dysphagia or any condition that may affect drug absorption, e.g., gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy, inflammatory bowel disease;\n9. History of organic heart disease, heart failure, myocardial infarction, angina pectoris, arrhythmia, ventricular tachycardia, clinically symptomatic AV block, long QT syndrome, or family history of long QT syndrome (evidenced by genetic proof or sudden cardiac death of a close relative at a young age);\n10. Major surgery within 6 months prior to the screening period, or surgical incision not fully healed; Major surgery includes, but is not limited to, any procedure with significant bleeding risk, prolonged general anesthesia, incisional biopsy, or significant traumatic injury;\n11. Allergic constitution, e.g., known history of allergy to two or more substances; Or judged by the investigator as potentially allergic to the investigational drug;\n12. Hemorrhoids or perianal diseases with regular\u002Fongoing hematochezia, irritable bowel syndrome, inflammatory bowel disease.\n\n    Lifestyle Habits:\n13. Habitual constipation or diarrhea;\n14. Alcoholism or regular alcohol consumption within 6 months prior to screening, i.e., alcohol intake exceeding 14 units per week (1 unit = 360 mL beer, or 45 mL spirit with 40% alcohol, or 150 mL wine), or a breath alcohol test result ≥20 mg\u002FdL at screening, or inability to abstain from alcohol during the trial period;\n15. Smoking \\>5 cigarettes per day or habitual use of nicotine-containing products within 3 months prior to screening, or inability to abstain during the trial period;\n16. Drug abuse or use of soft drugs (e.g., cannabis) within 3 months prior to screening, or use of hard drugs (e.g., amphetamines, phencyclidine) within 1 year prior to screening; Or positive urine screen for drugs of abuse during the screening period;\n17. Habitual consumption of grapefruit juice or excessive tea, coffee, and\u002For caffeinated beverages, and inability to abstain during the study period.\n\n    Others:\n18. Participation in a radiolabeled drug trial within 1 year prior to screening, or participation in a 14C-labeled breath test within 3 months prior to screening;\n19. History of needle phobia or blood phobia, difficulty with blood collection, or inability to tolerate venous puncture;\n20. Participation in any other clinical trial (including drug and device trials) within 3 months prior to the screening period;\n21. Vaccination within 1 month prior to screening, or planned vaccination during the study period;\n22. Plan to father a child or donate sperm during the study period or within 1 year after study completion, or disagreement to use strict contraceptive measures (see Appendix 1) for themselves and their partners during the study period and within 1 year after study completion;\n23. Blood loss or blood donation of ≥400 mL within 3 months prior to screening, or blood transfusion within 1 month;\n24. Any other factor that, in the investigator's opinion, makes the participant unsuitable for participation in this trial.",true,"MALE","45 Years",{"count":52,"type":21},8,"INTERVENTIONAL",[55],"PHASE1","This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg\u002F5 µCi dose of \\[14C\\]Zorifertinib in healthy Chinese adult male participants. The study includes a screening period (Day -14 to Day -1) and a dosing and observation period (Day 1 to Day 14). Blood, urine, and feces samples will be collected to measure radioactivity, drug concentrations, and metabolites. Safety will be assessed by adverse events, vital signs, laboratory tests, 12-lead ECG, and ophthalmic examinations. The target total radioactivity recovery is ≥90% of the administered dose.",[58,26],"EGFR Mutant Advanced Non-small Cell Lung Cancer","NOT_YET_RECRUITING","2026-06-01",{"date":62,"type":32},"2026-06-03",{"date":64,"type":21},"2026-06",{"date":66,"type":21},"2026-08",{"name":68,"class":69},"Alpha Biopharma (Jiangsu) Co., Ltd.","INDUSTRY",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100603940","a-prospective-cohort-study-of-zorifertinib-as-a-first-line-treatment-in-patients-with-epidermal-growth-factor-receptor-mutant-advanced-non-small-cell-lung-cancer-with-central-nervous-system-cns-metastases-100603940","NCT07143045","A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases","Inclusion criteria:\n\n1. Male or female, aged ≥18 years.\n2. Histologically or cytologically confirmed NSCLC with EGFR sensitizing mutations (including L858R or Exon 19Del), ineligible for curative surgery or radiotherapy.\n3. CNS metastases diagnosed as brain metastases (BM) and\u002For leptomeningeal metastases (LM) by imaging and\u002For cerebrospinal fluid pathological examination.\n4. Planning to receive zorifertinib (zorifertinib group) or other anti-tumor treatments (other treatment group) as first-line treatment.\n5. Voluntarily agreeing to participate in this study and signing the informed consent form.\n\nExclusion criteria:\n\n1. Currently participating or planning to participate in any interventional clinical study for first-line treatment (patients who have participated in non-interventional, real-world studies may still be included).\n2. Other reasons that, in the Investigator's opinion, make the patient unsuitable for this study.\n\nFor patients in Cohort A of the zorifertinib group, the following inclusion\u002Fexclusion criteria of the EVEREST study must also be met:\n\nInclusion Criteria A:\n\n1. . No prior treatment with chemotherapy, EGFR-TKIs, biological therapy, immunotherapy, or any investigational drug that is considered first line treatment for advanced NSCLC.\n2. . Eligible patients are not candidates for definitive surgical resection or radiation of all lesions in the opinion of the treating physician.\n3. . All patients must be stable without any systemic (oral or parenteral) corticosteroid or anticonvulsant therapy for at least 2 weeks prior to study treatment. Inhaled non-absorbable and topical corticosteroid use are permitted as indicated.\n4. . Patients may have prior placement of a properly functioning CNS shunt or Ommaya reservoir.\n5. . ECOG performance status 0 or 1, with no deterioration over the past 2 weeks, and expected survival time ≥ 3 months.\n6. . Women of child-bearing potential (WOCBP) and male patients should agree to take medically acceptable contraception measures while on study treatment and for 3 months following completion of study treatment. All WOCBP must have a negative pregnancy test at screening.\n7. . Patients with measurable CNS lesions must have at least one site of CNS lesion, which has not been previously irradiated, can be accurately measured at baseline as ≥ 10 mm in the longest diameter by MRI, and is suitable for accurate repeated measurements. Measurable extracranial lesions are not required. Patients with non-measurable CNS lesions must have at least one extracranial lesion, which has not been previously irradiated, can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except for lymph nodes which must have a short diameter ≥ 15 mm) by CT\u002FMRI, and is suitable for accurate repeated measurements.\n\nExclusion Criteria A:\n\n1. . Prior treatment with EGFR-TKIs (if EGFR-TKIs were used as adjuvant therapy, patients may be enrolled if the time from discontinuation to relapse meets the following requirements: \\>6 months for Cohort A, and \\>3 months for Cohorts B and C).\n2. . Positive for T790M mutation documented by central or local laboratory using an approved or validated test method, or documented positive KRAS or cMET.\n3. . Patients who have received any investigational drug, biological therapy, or immunotherapy for their malignant tumors within the past 21 days.\n4. . Patients who have had a major surgical procedure (excluding the need for placement of vascular access or a CNS shunt), or significant traumatic injury within 4 weeks of the first dose of study treatment, or have an anticipated need for major surgery during the study.\n5. . Presence of only leptomeningeal metastases (LM) disease confirmed by MRI and\u002For positive cerebrospinal fluid (CSF) pathology, with no brain metastases (BM).\n6. . Prior radiation therapy for CNS metastases that involves measurable or non-measurable sites of disease to assess efficacy.\n7. . Patients who have received radiation to more than 30% of the bone marrow within 2 weeks before the first dose of study treatment.\n8. . Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of study treatment) certain medications or herbal supplements that are known to be potent inhibitors or inducers of CYP3A4\u002F5 (see Appendix A).\n9. . Unmanageable nausea and vomiting, chronic gastrointestinal diseases, or prior gastric resection or surgical procedure that may interfere with adequate absorption of study drug.\n10. . History of concurrent and\u002For other active malignant tumors requiring treatment within 5 years of study treatment, excluding prior treated squamous cell carcinoma or basal cell carcinoma or carcinoma in situ.\n11. . History of any type of documented interstitial lung disease or radiation pneumonitis.\n12. . Presence of any severe or uncontrolled systemic disease or condition, including: (i) uncontrolled hypertension or diabetes; (ii) serious cardiac, pulmonary or renal disorders; (iii) active bleeding diatheses; (iv) any active type of bacterial, viral, fungal or other infection that would pose a significant risk to the patient in the opinion of the Investigator; or (v) active hepatitis B virus positive (defined as hepatitis B surface antigen (HBsAg) positive or hepatitis B core antibody (HBcAb) positive, and hepatitis B DNA positive (or detectable) or above the cut-off value) or positive HCV antibodies or positive HIV test result.\n13. . Women who are pregnant or lactating. WOCBP and fertile men with a WOCBP-partner not using adequate contraception measures.\n14. . Patients with unstable and symptomatic metastases: Any unstable and symptomatic CNS or distant metastasis that is not symptomatically controlled by prior surgery, radiotherapy or corticosteroid therapy within 2 weeks of initial study treatment.\n15. . Any unresolved toxicities from prior therapy, greater than Common Terminology Criteria for Adverse Events (CTCAE 5.0) Grade 1 at the time of starting study treatment, with exception of alopecia.\n16. . Patients with a significant cardiovascular disorder or condition, including any of the following:\n\n    1. Congestive heart failure (CHF) currently requiring treatment and patients with New York Heart Association (NYHA) Class III\u002FIV CHF (see Appendix B).\n    2. Need for antiarrhythmic drug therapy for a ventricular arrhythmia or patients with uncontrolled or unstable arrhythmias.\n    3. Severe conduction disturbance (e.g., second- or third-degree AV block).\n    4. Angina pectoris requiring treatment.\n    5. QTc interval \\> 450 msec (males) or \\> 470 msec (females).\n    6. History of congenital long QT syndrome, congenital short QT syndrome, Torsades de Pointes, or Wolff Parkinson White syndrome.\n    7. Left ventricular ejection fraction (LVEF) \\\u003C50% as determined by echocardiography or MUGA scan.\n    8. Myocardial infarction diagnosed within the past 6 months.\n17. . Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:\n\n    1. Absolute neutrophil count \\\u003C1.5 × 109\u002FL.\n    2. Platelet count \\\u003C100 × 109\u002FL (Transfusion-dependent patients are excluded from this study).\n    3. Hemoglobin \\\u003C90 g\u002FL.\n    4. Alanine aminotransferase (ALT) \\> 2.5 times the upper limit of normal (ULN) in the absence of documented metastases to liver or \\> 5 times the ULN in the presence of metastases to liver.\n    5. Aspartate aminotransferase (AST) \\> 2.5 times the ULN in the absence of documented metastases to liver or \\> 5 times the ULN in the presence of metastases to liver.\n    6. Total bilirubin \\> 1.5 times the ULN in the absence of metastases to liver or \\>3 times the ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or metastases to liver.\n    7. Creatinine \\>1.5 times the ULN concurrent with creatinine clearance \\\u003C50 mL\u002Fmin (measured or calculated by Cockcroft-Gault equation). Confirmation of creatinine clearance is only required when creatinine is \\>1.5 times the ULN.\n    8. If bone metastases are present and liver function is otherwise considered adequate by the Investigator, then isolated elevated alkaline phosphatase (ALP) is not an exclusion criterion.\n18. . History of hypersensitivity to active or inactive excipients of the study drug or drugs with a similar chemical structure or class to the study drug.\n19. . Judgment by the Investigator that the patient should not participate in the study if the patient is unwilling to comply with all study procedures and treatment.\n20. . History of recent stroke (\\\u003C6 months), or prior central nervous system injury that has persistent neurologic deficits that would affect neurologic assessments.\n21. . Significant medical or psychiatric illness that would interfere with the compliance to the protocol and ability to tolerate treatment.\n22. . Patients who have received any anti-neoplastic herbal medicines for their malignant tumors within the past 2 weeks.",{"count":77,"type":21},800,"This study is a patient-centered, two-group, three-cohort, multi-center, prospective study to further evaluate the survival benefits and safety of zorifertinib as a first-line treatment in EGFRm+ advanced NSCLC patients with CNS metastases, and to compare the clinical value of zorifertinib with other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).",[58,26],"2026-02-06",{"date":82,"type":32},"2026-02-09",{"date":84,"type":32},"2025-12-29",{"date":86,"type":21},"2031-11",{"name":68,"class":69},34]